Certificate of Analysis



CAR Receptor Booster

Catalog No. Amount Lot Number

631470 20 rxns Specified on product label.

Description

The CAR Receptor Booster increases the transduction efficiency of target cells to infection by adenovirus. The CAR Receptor Booster consists of exosome-like particles coated with adenoviral receptor protein CAR. When applied to target cells, fusion of the particles with the host cell plasma membrane temporarily increases surface levels of CAR to allow for efficient adenoviral transduction. Additionally, CAR Receptor Booster renders cells that cannot usually be transduced with adenovirus (e.g. hematopoietic cells) susceptible to infection.

Package Contents

• 200 μl CAR Receptor Booster

Storage Conditions

• Store at -70° C.

Expiration Date

• Specified on product label.

Storage Buffer

• Supplied in a PBS-based (phosphate-buffered saline) formulation.

Shipping Conditions

• Dry ice

Product Documents

Documents for our products are available for download at <u>takarabio.com/manuals</u> The following documents apply to this product:

- Viral Receptor Booster Protocol-At-A-Glance
- Adeno-XTM Adenoviral System 3 User Manual

Quality Control Data

CHO-K1 cells were treated with $10~\mu l$ of the CAR Receptor Booster and then transduced with LacZ-expressing adenovirus produced with the Adeno-X Adenoviral System 3. After 48 hours, greater than 50% of the treated CHO-K1 cells were transduced with adenovirus as determined by beta-galactosidase staining.

It is certified that this product meets the above specifications, as reviewed and approved by the Quality Department.



CAR Receptor Booster

CATALOG NO.

631470

NOTICE TO PURCHASER:

Our products are to be used for **Research Use Only**. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.

Your use of this product is also subject to compliance with the licensing requirements, listed below if applicable, and described on the product's web page at http://www.takarabio.com. It is your responsibility to review, understand and adhere to any restrictions imposed by these statements.

STATEMENT 225

Gesicle Technology. This product and its use are the subject of European patents and patent applications related to EP09306091, owned by Inserm Transfert. For research use only – not for therapeutic or diagnostic use in humans. No rights granted other that the right to use for research purposes.

In addition, Inserm Transfert is the owner of European patent application EP09306092.9 relating to the use of microvesicles for cell engineering purposes. The products should not be used to develop, make, have made, use and sell or otherwise distribute any product, composition, method, service or process for commercial services that would infringe said patent application, unless a license is negotiated with Inserm Transfert, at 7 rue Watt, 75013 Paris, France (www.inserm-transfert.fr).

TRADEMARKS:

©2023 Takara Bio Inc. All Rights Reserved.

All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions.

Takara Bio USA, Inc.

2560 Orchard Parkway, San Jose, CA 95131, USA U.S. Technical Support: technical support@takarabio.com

United States/Canada **Asia Pacific** Europe Japan 800.662.2566 +33.(0)1.3904.6880 +81.(0)77.565.6999 7/6/2023